Document is current
Any future updates will be listed below
-
Authors
Takahashi, Koichiro https://orcid.org/0000-0003-0461-5072
Makita, Naoyuki
Castañeda-Sanabria, Johann
Argoubi, Ramzi https://orcid.org/0000-0002-3171-0078
Nowacki, Grégoire
Issa, Seham https://orcid.org/0000-0002-1854-1839
Matsumoto, Isao
Yoshida, Yuri
Müllerová, Hana https://orcid.org/0000-0002-0949-0101
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 11 June 2024
Accepted: 6 September 2024
First Online: 16 October 2024
Declarations
:
: Koichiro Takahashi has received honoraria (lecture fees) from AstraZeneca. Naoyuki Makita, Isao Matsumoto, Yuri Yoshida, and Hana Müllerová are employees of AstraZeneca and may hold stock and/or stock options in the company. Johann Castañeda-Sanabria is a former employee of AstraZeneca and a current employee of IQVIA Real World Solutions, Global Epidemiology and Database Studies. Ramzi Argoubi, Grégoire Nowacki, and Seham Issa are employees of Oracle Life Sciences (formerly Cerner Enviza), which was contracted by AstraZeneca to conduct the study.
: The study protocol was approved by the NPO-MINS Institutional Review Board (Approval No. 220216) in July 2022. This observational study was performed in accordance with ethical principles consistent with the Ethical Guidelines for Biomedical Research Involving Human Subjects, the Declaration of Helsinki, and the Japanese Act on the Protection of Personal Information. Permission was obtained to access and use the data from the MDV database. Informed consent was waived because the data were anonymized.
